Serum infrared spectroscopy to identify gliomas and lymphomas

In the UK, more than a third of patients with brain tumours have seen a GP more than five times before diagnosis, and 62 per cent have been admitted to hospital during an emergency episodeThere is no early detection of brain tumours, so a quick diagnosis is urgently neededAttenuation of the full-reflected Fourier-transform infrared spectroscopy (ATR-FTIR) analyzes a wide range of macromolecules and is sensitive to cancer characteristicsThe combination of serum infrared spectroscopy and advanced data analysis can quickly identify brain tumors and their malignancyIn recent years, scholars have developed a new high-throughput attenuation full-reflection technology, which has good clinical transformation potential and is cost-effective for the NHS in EnglandJames MCameron, of the Department of Theoretical and Applied Chemistry at Strathclyde University in Glasgow, UK, and others used the new method to study infrared spectroscopy to diagnosebrain tumours and identify gliomas and lymphomasThe article was published in the November 2019 issue of The Journal of Analystthe studyincluded 487 patients with brain tumors and 237 healthy controls, collected 765 serum samples from patients with brain tumors and healthy controls, and conducted the largest infrared spectroscopy study to dateThe authors use a new high-throughput ATR-FTIR spectral technology based on the internal reflective element of SIRE, and use three kinds of machine learning, namely, random forest, least-partial square-by-component analysis (PLS-DA) and support vector machine for spectral analysisthe resultsthe first use of new high-throughput technology to diagnose brain tumors and non-tumor control; The average sensitivity and specificity of the PLS-DA model were 90.5% and 91.1%, respectively, and the average sensitivity and specificity of the linear support vector machine were 92.1% and 88.7%, respectivelyIn addition, the authors collected blood samples from 41 patients with intracranial lymphomaHighly invasive glioblastoma (GBM) and primary central nervous system lymphoma (PCNSL) are similar in magnetic resonance imaging, making it difficult to distinguish between medical imaging, while infrared spectroscopy is 90.1% and 86.3% sensitivity and specificity, respectively, in distinguishing GBM and PCNSL patientsconclusions
rapid detection of serum infrared spectroscopy for early diagnosis of brain tumors may have a significant impact on improving patients' prognosis and quality of life Infrared spectroscopy and its new analytical technology can be applied clinically, and reliable serum infrared spectroscopy diagnosis avoids surgical biopsy to a certain extent and accelerates access to chemotherapy.